All News
Women with Rheumatic Disease (11.4.2022)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Read Article
Undiagnosed RA During the Pandemic
d
EurekAlert!
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
Read Article
Full read review of advances in bone biology leading to drug development (denosumab, romosuzumab, Burosumab), advances in Pagets and rickets and key regulatory molecules for bone remodeling, RANK, RANKL, OPG, & sclerostin https://t.co/CMMzIrZRUa https://t.co/ABhaHxP8y2
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Patricia Harkins, @DrTrishHarkins, is new to the #ACR22 RheumNow reporter team.
From Dr. Harkins, "I am really looking forward to the new "Ignite sessions", as well as working with the Rheum Now Faculty for the first time!"
Follow her for real-time #ACR22 coverage! https://t.co/dpDfNJs1V4
Dr. John Cush RheumNow ( View Tweet)
"I can't wait to see how the new format works: the poster hall, the SPARK talks, and to see a whole lot of people in person!"
Follow Dr. David Liew, @drdavidliew, for real-time #ACR22 coverage! https://t.co/RBbLyqrBNT
Dr. John Cush RheumNow ( View Tweet)
Drug-induced Hepatotoxicity - many Rheum drugs on the list: Tylenol, azathioprine, allopurinol, cyclosporine, dapsone, gold, MTX, 6-MP, NSAIDs, ASA, SSZ, Minocin... https://t.co/tAaW41h7xS https://t.co/fn8sNbeslH
Links:
Dr. John Cush RheumNow ( View Tweet)
From the Crypt: Rheumatology Dead Word Cemetery
Arthritis, Rheumatic Disease and Rheumatology cover a catalogue of ageless disorders w/decades, if not centuries, of history behind them.Enjoy our blog on retired Rheum sayings, as so decreed by RheumNow.
https://t.co/WyBFEVa1h5 https://t.co/eE3HQ4N5Ia
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 New Drug Approvals
Download today!
https://t.co/nz91Ckw0AZ https://t.co/QieTvcqjcy
Links:
Dr. John Cush RheumNow ( View Tweet)
One week away! #ACR22 https://t.co/bvFCfFpQom
Dr. John Cush RheumNow ( View Tweet)
“I am looking forward to the ACR to hear about the ground-breaking results from basic science to the new treatments. I am delighted to be part of the RheumNow faculty covering the many topics from #ACR22. “
Follow Dr. Chan at @synovialjoints for real-time coverage of #ACR22. https://t.co/i6OZRHlBaE
Dr. John Cush RheumNow ( View Tweet)
New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
This and more on the latest RheumNow podcast.
https://t.co/4YBqHjI3VL https://t.co/g2pE72pyEk
Links:
Dr. John Cush RheumNow ( View Tweet)
“At the ACR I am looking forward to meeting colleagues in person, having some great food in Philadelphia and to learning alot as a RheumNow reporter!”
Dr. Janet Pope is back for #ACR22 as a RheumNow reporter, sharing real-time coverage on many topics. Follow her @Janetbirdope https://t.co/ROD7oan4KZ
Dr. John Cush RheumNow ( View Tweet)
SLE T2T - Lupus Low Disease Activity State Predicts Outcomes
A prospective study shows that T2T with a goal of LLDAS and remission has been shown to improve mortality risk.
https://t.co/WRaqjdVi9G https://t.co/3guKt0Qby9
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 CDC Clinical Practice Guideline on Opioid Prescribing
The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute, subacute, and chronic pain.
https://t.co/aFE4fUpIWn https://t.co/kG8QlVy2bG
Links:
Dr. John Cush RheumNow ( View Tweet)
Population study shows among vaccinated gout pts, COVID breakthrough infection occurred in @ 4.68/1K Pt-mos vs 3.76/1K Pt-mos in non-Gout persons. Gout w/ Covid had More Hosp (aHR=1.30) & death (aHR=1.36), moreso in Women w/ gout (aHR 1.55 & 2.46) https://t.co/ViwiPzqTbZ https://t.co/BrXd6pbgRI
Links:
Dr. John Cush RheumNow ( View Tweet)
Multinatinal cross-sectional survey of 2270 PsA pts shows despite comparable Dz duration, presentation, biologic use (54%), Women had worse QOL, more disability and work activity impairment (but less comorbidities) https://t.co/1KbDuxaMFf https://t.co/SsbSHQNsPV
Links:
Dr. John Cush RheumNow ( View Tweet)
BIOBADASER registry study of 969 axSpA pts (315 females, 654 males; 2000-2019) who initiated a TNFi shows nonresponse (BASDAI50) was more likely in women (p=0.018), older age at the start of TNFi therapy. https://t.co/Zp7PWhEMav https://t.co/1XY0dC0QCW
Links:
Dr. John Cush RheumNow ( View Tweet)
Single center study from UAB shows 72 gout pts treated & D/C from ED were Rx w/ steroids (64%), opioids (63%), NSAIDs (43%), colchicine (32%). But only 26/72 (36%) had subsequent outpatient clinic visit for gout. https://t.co/I8jjqIqJXd https://t.co/05YSibd6iz
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitor labeling in Canada updated to include risks of MACE, fatal VTE and cancer for tofacitinib (Xeljanz) (also applied to Cibinqo, Inrebic, Jakavi, Olumiant, Rinvoq Xeljanz) https://t.co/FEbHE4wN3I https://t.co/EN80i9cY5h
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Chao will be covering PsA and AS for the RheumNow team at #ACR22.
“I’m looking forward to the exciting hybrid format of both in person and virtual meeting this year!”
Follow @doctorRBC for real-time #ACR22 coverage. https://t.co/3sbBhVPPZ2
Dr. John Cush RheumNow ( View Tweet)
